COMMUNIQUÉS West-GlobeNewswire

HNL Lab Medicine Celebrates Preferred Partnership With Roche Diagnostics
07/04/2026
ALLENTOWN, Pa., April 07, 2026 (GLOBE NEWSWIRE) -- HNL Lab Medicine today announced a preferred partnership with Roche Diagnostics. This partnership aligns HNL Lab Medicine with an organization that shares its focus on [...]
Regional Health Properties Reports Fourth Quarter 2025 Results
07/04/2026
Reported Full Year Profitability of $3.4 million Repurchased 511,099 Series B Preferred Shares HealthCare Services segment reports 20% growth in Average Daily Census ATLANTA, GA, April 07, 2026 (GLOBE NEWSWIRE) -- [...]
MEDX HOLDINGS REPORTS STRONG Q4 RESULTS, ACHIEVES NET PROFITABILITY, AND ANNOUNCES STRATEGIC PARTNERSHIPS TO SUPERCHARGE FRANCHISE EXPANSION
07/04/2026
MEDX HOLDINGS REPORTS STRONG Q4 RESULTS WITH PLANS TO DISRUPT THE ALCOHOL INDUSTRY Austin , Texas, April 07, 2026 (GLOBE NEWSWIRE) -- FOR IMMEDIATE RELEASE MEDX HOLDINGS REPORTS STRONG Q4 RESULTS, ACHIEVES NET [...]
Death by a Thousand Vendors: 81% of Employers Are Hiring Just to Keep Up with Digital Health Vendor Sprawl
07/04/2026
Solera Health research reveals the operational & administrative cost of managing digital health vendors is rivaling the savings they were designed to deliver PHOENIX, April 07, 2026 (GLOBE NEWSWIRE) -- More than 40 [...]
NexTel Medical Corp Announces Pivotal Milestone in Commercial Launch of Patent-Protected NANOG DNA Cancer Screening Test
07/04/2026
ORLANDO, Fla., April 07, 2026 (GLOBE NEWSWIRE) -- NexTel Medical Corp f/k/a Exousia Pro, Inc. ( OTCPK: MAJI ), a clinical-stage biotechnology leader specializing in proprietary exosome-based delivery systems, is proud [...]
Calidi Biotherapeutics Announces Speaker Presentation at ASGCT Conference in Boston on May 14, 2026 Highlighting the RedTail Platform’s Ability to Deliver Genetic Medicines to Distal Sites of Disease with Systemic Therapy
07/04/2026
SAN DIEGO, April 07, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, will [...]
Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension
07/04/2026
WILMINGTON, Del., April 07, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial [...]
NTG Nordic Transport Group A/S - Q1 2026 Conference Call
07/04/2026
NTG Nordic Transport Group A/S – Q1 2026 Conference Call We expect to release the Q1 2026 interim results of NTG Nordic Transport Group on the evening of May 5, 2026. A webcast and conference call will be held in the [...]
Corbus Pharmaceuticals Announces Broad Alignment with FDA on Registration Path for CRB-701 in Second-Line HNSCC and Cervical Cancer
07/04/2026
FDA feedback enables Corbus to proceed with proposed registrational study design and endpoints to support potential accelerated approval in second-line HNSCC and cervical cancer Updated CRB-701 monotherapy data accepted [...]
Xenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for Azetukalner in Focal Onset Seizures at 2026 AAN Annual Meeting
07/04/2026
Five abstracts accepted including Late-breaking Science oral and poster presentations of Phase 3 X-TOLE2 study results for azetukalner in focal onset seizures Poster presentations also include long-term efficacy and [...]
Clover Health Empowers Members to Take Charge of Their Health Data Through HealthEx Partnership
07/04/2026
Built on Counterpart Health infrastructure, the partnership gives members a secure way to access and share clinical and claims information through digital health tools WILMINGTON, Del., April 07, 2026 (GLOBE NEWSWIRE [...]
Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference
07/04/2026
SOUTH SAN FRANCISCO, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell [...]
20/20 BioLabs Selected by Evexia Diagnostics to Offer OneTest™ for Cancer Through Evexia Platform
07/04/2026
Joint Release Expands 20/20 BioLabs’ Testing Solutions Across Evexia’s Network of ~40,000 Functional and Integrative Medicine Practitioners Marks a Commercial Expansion Milestone for OneTest for Cancer Across Evexia’s [...]
Abeona Therapeutics® Announces Appointment of Keith A. Goldan to its Board of Directors
07/04/2026
CLEVELAND, April 07, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Keith A. Goldan as a new independent member to its Board of Directors, effective as of April 1, [...]
Moleculin Releases Next CEO Corner Segment Highlighting Annamycin’s Non-Cardiotoxic Profile
07/04/2026
Access the Moleculin CEO Corner here HOUSTON, April 07, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced it has released the next segment on its CEO [...]
Evaxion announces last patient visit in one-year extension of phase 2 trial with personalized cancer vaccine EVX-01
07/04/2026
Trial extension completed as planned with three-year clinical efficacy data expected to be presented in the second half of 2026 The trial has already yielded encouraging one- and two-year data including a 75% Objective [...]
Aclarion Highlights Growing Adoption of Nociscan at The London Clinic with New Physician Video
07/04/2026
Video featuring Mr. John Sutcliffe, Lead Clinician at The London Spine Clinic, highlights real-world physician experience with Nociscan in clinical practice Nearly 100 Nociscans performed at The London Clinic, [...]
Route 92 Medical Announces $50 Million Growth Financing
07/04/2026
New investor Sectoral Asset Management joins growth financing round to support acceleration of commercial growth WEST JORDAN, Utah, April 07, 2026 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a privately held medical [...]
Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDA
07/04/2026
ISELIN, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, [...]

Pages